🚨 New Podcast Ep.! NEALS 2025: Takeaways That Matter for ALS Care - Featuring Dr. Berry and Dr. Andrews! Listen as they reflect on key themes from the 2025 NEALS Annual Meeting, now reintroduced as the Network of Excellence for #ALS. 👂 ➡️ www.neurologylive.com/view/episode... #MindMoments #Podcast

Breakthrough for #Parkinson patients: iPSC therapy UX-DA001 boosts motor function & dopamine activity—without serious side effects. Learn how #CellTherapy may transform brain repair. 🧠 Read the full story 👉 www.neurologylive.com/view/therape... #StemCellTherapy #NeuroResearch #Neurology #Health

🌍 A new dawn for #RareDisease care: #FDA approves Kygevvi, the first treatment for thymidine kinase 2 deficiency (TK2d). 💡 Data show an 86% reduction in mortality risk — a life-changing advance for patients & families. Read here: www.neurologylive.com/view/neurovo... #Neurology #Innovation

Caregivers are open to talking about social determinants of health (SDoH) — but prefer surveys over face-to-face discussions. A new study finds many want to focus clinic time on their child’s care while still sharing key life factors that affect health. 🔗 ➡️ www.neurologylive.com/view/study-s...

🧠 This Week on #NeurologyLive From conference coverage to video interviews to up to the minute news — we’re diving into the latest research, expert insights, and clinical updates shaping the field of #neurology. Don’t miss this week’s coverage 👉 www.neurologylive.com #BrainHealth #NeurologyUpdates

⚡ EVs may reduce emissions — but could they raise neurologic risks globally? Dr. Brad Racette (Barrow Neurological Institute) explores how EV production shifts environmental & neurotoxic burdens to the global south. Read more 👉 www.neurologylive.com/view/overvie... #EVs #Risks #Neurology #Health

💡 Promising results for #ALS patients! Phase 2a data show SPG302 (Spinogenix’s synaptic regenerative drug) slowed ALS progression by 76% vs historical controls, with 82% of patients showing stable or improved function. Read more: www.neurologylive.com/view/prelimi... #Neuroscience #Neurology

In case you missed it: 🚨 Breaking: FDA Approves First Treatment for TK2 Deficiency The #FDA has approved Kygevvi — a fixed-dose combo of doxecitine + doxribtine — as the first-ever therapy for thymidine kinase 2 deficiency. Stay up to date here: www.neurologylive.com/view/fda-app... #Neurology

A new #Phase3 trial, RELIEVE, is underway to evaluate remibrutinib, a potent oral BTK inhibitor, in #gMG. 💊 Builds on strong safety data from autoimmune studies and FDA approval in CSU. 🧬 Could mark a new era in targeted gMG treatment. Read here: www.neurologylive.com/view/new-pha... #Neurology

🧠 This Week on NeurologyLive® — Nov 3, 2025 From #Alzheimer’s and #epilepsy to sleep and stroke, we’re diving into the week’s hottest topics in neurology. Explore expert insights, in-depth analyses, and clinical updates designed for professionals in the field. 🔗 neurologylive.com #Neurology #Care

The results from our #AI in #MultipleSclerosis survey are in. Take a look over on @neurologylive.bsky.social. www.neurologylive.com/view/ai-in-m...

🎃 This Halloween, neurology meets history 📜 Avi Singh Gandh, MD, explores how the “bewitchments” of the 1692 Salem Witch Trials may reflect epilepsy, FND, and more —reminding us how science turns fear into understanding. Read more: www.neurologylive.com/view/revisit... #Halloween #AAN25 #Spooky

This #WorldStrokeDay, Cleveland Clinic’s Dr. Andrew Russman highlights how most strokes stem from identifiable and modifiable risks — and how precision medicine and heart–brain collaboration are reshaping prevention. Read more via NeurologyLive®: www.neurologylive.com/view/honorin...

❤️ “Maintaining healthy numbers for Life’s Essential 8 can reduce the risk of #stroke and #dementia.” — Dr. Mitch Elkind Ahead of #WorldStrokeDay, NeurologyLive® spoke with Dr. Elkind on prevention, equity, and the future of brain health. Read more: www.neurologylive.com/view/neurovo... #Health

🚨 FDA Accepts NDA for MK-6240 — a PET imaging agent targeting tau protein in #Alzheimer disease. 🔬 Developed by Lantheus, MK-6240 aims to improve early diagnosis and guide treatment strategies for patients with cognitive impairment. 📖 Read more: www.neurologylive.com/view/fda-acc... #FDA #News

This Week’s Preview 🫣 Stay ahead in neurology with our latest coverage! Coming up: exclusive clinician interviews, continued conference insights, a new podcast episode, and more. 🕐 Take 5 minutes to stay informed → www.neurologylive.com/view/this-we... #Neurology #Research

"Lifestyle factors are not secondary—they’re central" New insights from Dr. James N. Brenton at the 2025 Child Neurology Society Annual Meeting on how #diet, vitamin D, and obesity impact pediatric MS progression—and why coordinated care matters. Full article: www.neurologylive.com/view/integra...

🧠 The NeurologyLive® team was on-site at #MDS2025 in Honolulu, bringing you exclusive interviews and updates from the floor! Hear from experts like Jonas Hannestad, MD, PhD, on the latest in Parkinson’s disease research and novel therapies: Check out the 🔗 here: www.neurologylive.com/view/mds-con...

🚨 Registration is OPEN! 🚨 Join us March 8–11, 2026 in Orlando for the #MDAConference, the leading global event for neuromuscular care & research. 🌍🧬 🔗 Register now: www.mdaconference.org #MDA #MuscularDystrophy #neuromuscular

🚨 Just launched: our expert interview collection from AAIC 2025! From novel blood-based biomarkers to tau-targeting therapies and scalable digital tools, top researchers and clinicians shared insights into where Alzheimer care is headed. 🧠 Take a look→ www.neurologylive.com/view/aaic-20...

🧠🤔 In our Q&A, MIT’s Daniel Freedman, PhD, explains how Openwater’s Open-LIFU is enabling precise deep-brain access for studying how the conscious experience arises from brain activity, exploring treatments for pain, depression, and more. Read now: www.neurologylive.com/view/openwat...

🚨FDA has approved fremanezumab (Ajovy) as the first anti-CGRP preventive treatment for pediatric episodic migraine, expanding care options for children and adolescents aged 6 to 17. Approval was supported by phase 3 SPACE study results. 📰Read more now: www.neurologylive.com/view/fda-app...

🧠 #AAIC25: ABvac40, a developing Alzheimer vaccine from Grifols, showed a significant reduction in cognitive decline in a phase 2 trial, and all met primary endpoints with no significant safety concerns 👏 Read more now: www.neurologylive.com/view/alzheim...

🧠 At #AAIC25, Sharron Gargosky, PhD, shared promising early data from Spinogenix’s phase 2 trial of SPG302 in #AD. The synaptogenic small molecule showed early signs of cognitive improvement and was well tolerated over 28 weeks 👏 Read more now: www.neurologylive.com/view/finding...

🧠 As patients grow up, care must grow with them, and support makes all the difference. In this new feature, Susan Duberstein, MD, PhD, outlines how continuity of care, patient education, and psychosocial support can smooth this critical journey ❤️ Learn more: www.neurologylive.com/view/the-tra...

The EMA’s CHMP has issued a negative opinion on the conditional marketing authorization for Elevidys, Sarepta/Roche’s gene therapy for DMD, citing missed primary endpoints in the EMBARK trial 🧬🤔 💻Read more: www.neurologylive.com/view/ema-iss...

New in hypersomnia research: In Ep. 4 of our SLEEP 2025 series, experts Eric Olson, MD, & Anita Shelgikar, MD, discuss the phase 2 Vibrance-3 trial of orexin-2 agonist ALKS 2680, presented at the #SLEEP2025 meeting 😴 📲Watch now: www.neurologylive.com/view/vibranc...

Major neurology trial readouts expected in 2H 2025 may redefine standards of care. Check out our curated list, including PERSEUS (tolebrutinib in PPMS) and azetukalner (for focal seizures), for insights into next-gen therapies 👀 📲Read now: www.neurologylive.com/view/eyeing-...

🧠💻 Can AI help identify cardiovascular risk in patients with #migraine? New data from #AHS2025 suggest AI-ECG tools, including atrial fibrillation prediction and delta age, may be effective for early detection of adverse vascular events. 🔗Read more now: www.neurologylive.com/view/explori...

FDA clears HyHub & HyHub Duo: new needle-free devices that simplify Hyqvia infusion for #CIDP, cutting down prep time and supplies. A major step forward in at-home or clinic-based treatment. The launch expected in late 2025 👀 📘Read more now: www.neurologylive.com/view/fda-cle...

Praxis Precision Medicines advances relutrigine for rare epilepsy, achieving FDA breakthrough status and promising results in ongoing clinical trials.👏 Read more now: www.neurologylive.com/view/breakth...

🎧🎙️ A special Mind Moments® episode with Stewart Tepper, MD, just dropped! Tune in as we unpack the FDA’s latest #migraine therapy approvals, STS101 and CT-132, and explore what these innovations mean for care, access, and outcomes. 🧠Listen now: www.neurologylive.com/view/special...

In this video, James Galvin, MD, MPH, explains how the CARM score uses 3 cognitive subtests and machine learning to estimate amyloid risk, helping clinicians assess whether cognitive impairment may be due to Alzheimer's and guide next steps in care 📽️ Watch now: www.neurologylive.com/view/overvie...

In episode 2 of our latest podcast, expert panelists break down the clinical signs, diagnostic strategies, and treatment options for #narcolepsy, offering practical insights for health care professionals new to the field ⚕️ 🎧 Listen here: www.neurologylive.com/view/video-n...

New VHA data show stroke risk in migraine isn’t limited to women or those with aura. At #AHS2025, Elizabeth Seng, PhD, discussed why sex differences matter in how we interpret and treat migraine 🧠 📹Watch now: www.neurologylive.com/view/using-v...

🎙️ Episode 145 of Mind Moments® is live! In this episode, Joyce Lee-Iannotti, MD, PhD, shares expert insights from the #SLEEP2025 joint meeting on emerging research at the intersection of #stroke, #sleep, and neurorestoration. 🧠 Listen now: www.neurologylive.com/view/episode...

FDA has approved Exablate Neuro for staged bilateral use in advanced #Parkinson disease. This noninvasive, MRI-guided ultrasound tech targets the brain with no cuts or implants. A safer step forward in neuro care. 🧠⚕️ Read more now: www.neurologylive.com/view/exablat...

📰FDA approves updated label for donanemab (Kisunla) with a new titration schedule to reduce ARIA risk in early-stage #Alzheimers. A promising step toward safer, more targeted anti-amyloid therapy. 🧠 🔗Read more now: www.neurologylive.com/view/fda-app...

🚨 The FDA has granted priority review to Denali Therapeutics’ tividenofusp alfa, a brain-penetrant therapy for Hunter syndrome (#MPSII). The decision represents the urgent need for treatments targeting neurological symptoms in patients. 🔗Read more now: www.neurologylive.com/view/fda-gra...

🔬 Dravet and Lennox-Gastaut may share trial headlines—but they’re clinically distinct. In our latest podcast episode, Dr. Joseph Sullivan breaks down how to differentiate them, what new research shows, and how trials are evolving. 🎧 Listen now: www.neurologylive.com/view/episode...

#BREAKING: The FDA has approved an expanded indication on @gehealthcare.bsky.social’s PET imaging agent Vizamyl to include both quantification of amyloid burden for patients with suspected Alzheimer disease (AD) and use in therapy monitoring. Details: www.neurologylive.com/view/fda-gre...

Today is Dravet Syndrome Awareness Day 🤲✨ Dravet syndrome affects ~1 in 15,000–30,000 births and requires early diagnosis for better outcomes and access to life-saving treatments. A piece from the @curedravet.bsky.social: 📖 www.neurologylive.com/view/changin...

Multiple sclerosis isn’t just relapses and mobility issues. Fatigue, cognitive dysfunction, and emotional well-being matter too. Dr. Taylor Hess breaks it all down in our latest episode for #WorldMSDay 🎙️ ➡️ www.neurologylive.com/view/episode...

#CMSC2025 abstracts are live! Time to plan your schedule for this week. abstracts.ijmsc.org/cmsc2025/abs...

📈 Can we make remyelination a reality for patients with MS? This expert-led roundtable breaks down where we are, what’s working, and what hurdles remain in one of the most ambitious efforts in MS care. 👥 Featuring: Ari Green, MD Paul Tesar, PhD Watch here: www.neurologylive.com/roundtable-d...

BREAKING: The @fda.gov has cleared Fujirebio's Lumipulse G p-tau217/ß-Amyloid 1-42 Plasma Ratio as the first blood test for the diagnosis of #AlzheimersDisease. Data from a study of nearly 500 participants with MCI backed the decision. www.neurologylive.com/view/fda-cle...

📢 New Educational Series: Advances in SMA Treatments Join experts Diana Bharucha-Goebel, MD, and Bakri Elsheikh, MBBS, FRCP, as they explore key updates in SMA care—from newborn screening and early intervention to treatment decision-making across age groups. www.neurologylive.com/roundtable-d...

Introducing our latest series with @curesma.bsky.social!✨ Throughout this week, we will be launching episodes from this 6-part series each day, giving clinicians insights on the latest updates in treatment decisions for SMA🧬👶🧑‍⚕️ Episode 1 is now live: neurologylive.com/view/sma-tre...

I loved participating in this (thank you for the invite @neurologylive.bsky.social ). I am always happy to talk about aging and Alzheimer's disease in people with Down syndrome! @ucimind.bsky.social @ucirvine.bsky.social!

#ICYMI: Last week, we launched a new episode of our Mind Moments podcast, featuring commentary from special guest @elizabethhead.bsky.social! We talked about Down syndrome and Alzheimer's, the emerging research around these conditions, and much more🎤 www.neurologylive.com/view/episode...